Patent 7632806 was granted and assigned to Novo Nordisk on December, 2009 by the United States Patent and Trademark Office.
A method is disclosed for increasing the shelf-life of a pharmaceutical composition for parenteral administration comprising a glucagon-like peptide which is prepared from a peptide product that has been subjected to treatment at a pH above neutral pH.